CARA - Cara Therapeutics initiates Phase 2 trial of its lead drug candidate for pruritus treatment

Cara Therapeutics (CARA) announces the start of Phase 2 trial of Oral KORSUVA (difelikefalin) for the treatment of moderate-to-severe pruritus in patients suffering from notalgia paresthetica, a nerve disorder characterized by chronic pruritus of the upper to middle back.This 8-week long placebo-controlled study will evaluate the efficacy and safety of Oral KORSUVA moderate-to-severe pruritus in approximately 120 subjects. "Evaluating the ability to treat pruritus of a neuropathic origin, in addition to our current clinical development programs in systemic and dermatological chronic pruritus, will further support the potential of Oral KORSVUA™ as a broad anti-pruritic agent," says Joana Goncalves, M.D., CMO of Cara Therapeutics.In a ‘very bullish thesis’ written on Cara Therapeutics recently, Seeking Alpha contributor, D. H. Taylor, dubbed the company as 'a budding pharmaceutical company that may have a blockbuster on its hands.’

For further details see:

Cara Therapeutics initiates Phase 2 trial of its lead drug candidate for pruritus treatment